Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.78 | N/A | -0.45% |
management commentary, guidance changes, and full analysis available with Pro.
| -0.45% |
Tone: Cautiously Optimistic
Overall, management expressed a cautious outlook, acknowledging market pressures while reaffirming their focus on long-term growth strategies.
Management highlighted ongoing challenges in the market.
They emphasized their commitment to innovation despite current hurdles.
This earnings report indicates that Gilead Sciences faced some challenges during the quarter, as evidenced by the slight miss on EPS. The lack of revenue data and guidance leaves investors uncertain about future performance. The stock reaction is not available, which may reflect the market's wait-and-see approach regarding the company's strategic direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FORTINET INC
Feb 5, 2018